Table 1.
Clinical features of the 56 NPC patients included in the study.
| Characteristics | Number of patients | |
|---|---|---|
| Age, year (range 19–70 y, 47.07 ± 10.86, median = 48 y) | ||
| å ≤ 50 | 36/56 | 64.29% |
| >50 | 20/56 | 35.71% |
| Gender | ||
| Male | 34/56 | 60.71% |
| Female | 22/56 | 39.29% |
| Education, year | ||
| ≤9 | 8/56 | 14.29% |
| 10–12 y | 30/56 | 53.57% |
| >12 y | 18/56 | 32.14% |
| Histology, WHO type | ||
| Undifferentiated non-keratinized carcinoma | 51/56 | 91.11% |
| Differentiated non-keratinized carcinoma | 4/56 | 0.71% |
| Differentiated squamous cell carcinoma | 1/56 | 0.18% |
| Stage | ||
| II | 13/56 | 23.21% |
| III | 23/56 | 41.07% |
| IV | 20/56 | 35.71% |
| IMRT Dose, Gy | ||
| 68.2 | 7/56 | 12.50% |
| 69.75 | 21/56 | 37.50% |
| 70.06 | 18/56 | 32.14% |
| 72.1 | 10/56 | 17.86% |
| Chemotherapy | ||
| Cisplatin (30–40 mg/m2) weekly | 8/56 | 14.29% |
| Cisplatin (80–100 mg/m2) on days 1, 22, and 43 | 6/56 | 10.71% |
| Docetaxel (75 mg/m2) and Cisplatin (80–100 mg/m2) on days 1, 22, and 43 | 26/56 | 46.43% |
| Paclitaxel (175 mg/m2) and Cisplatin (80–100 mg/m2) on days 1, 22, and 43 | 16/56 | 28.57% |
NPC = nasopharyngeal carcinoma, IMRT = intensity-modulated radiotherapy.